Status:
RECRUITING
Remimazolam vs Propofol in Laser Burn Cases
Lead Sponsor:
Medical University of South Carolina
Conditions:
Burn Scar
Hypertrophic Scarring
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This randomized, single-blind, crossover study compares remimazolam and propofol for monitored anesthetic care during fractional ablative CO₂ laser therapy for burn scars. The primary aim is to assess...
Detailed Description
Patients will be randomized to receive either remimazolam or propofol during their first laser session, and the alternate drug during their second session 4-6 weeks later. Outcomes include respiratory...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Undergoing both outpatient Session #1 and Session #2 of fractional ablative CO2 laser therapy
Exclusion
- History of previous fractional ablative laser therapy for burn scar
- Procedure expected to last longer than 30 minutes
- Allergy such as dextran 40 or contraindication to either of the study drugs
- Pregnant and/or breastfeeding
- Subjects who are unable to or choose not to give informed consent
Key Trial Info
Start Date :
November 12 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT07213544
Start Date
November 12 2025
End Date
January 1 2027
Last Update
November 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of South Carolina
Charleston, South Carolina, United States, 29425